Pharmacyclics is committed to improving the quality and duration of life for cancer patients by resolving serious unmet medical needs. The company's small-molecule drug candidates are designed to target biochemical pathways involved in human diseases like cancer and immune mediated diseases. With the support of AbbVie, Pharmacyclics is striving to outsmart cancer and bring novel cancer treatments to market.